Lates News

According to AI Express of Daily Economic News, Dongwu Securities issued a research report on February 14th, giving Taige Medicine (300347.SZ) a "buy" rating. The reasons for the rating mainly include: 1) The domestic and international innovation drug financing environment continues to improve, coupled with the USD interest rate cut cycle and the continuation of the trend of innovative drugs going global, the demand for clinical CRO industry is expected to continue to expand; 2) Taige Medicine relies on its leading position in clinical CRO, the coordinated development of CTS and CRLS business, steady progress in core businesses such as global registration application, device services, drug vigilance, AI medical translation, and digital clinical trials; 3) Taige Medicine's leading advantages are significant, with the continuous strengthening of domestic business moats, continuous expansion of overseas business, and expectations of performance recovery with the improvement in industry conditions.